480 Biomedical Announces Initial Observations from OCT Sub-Study of the STANCE Trial Evaluating the First Self-Expanding Bioresorbable Scaffold for Superficial Femoral Artery Disease

The first 25 patients in 480 Biomedical's STANCE trial have been successfully implanted with the company's self-expanding, bioresorbable scaffold.... [more]

View complete Press Release article